Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.45 |
| ▸ | CNR2 | P34972 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608628 | 0.84 | CNR2 (0.48) | CNR1CNR2RAB9ANPC1ATM | |
| SCHEMBL30798372 | 0.78 | CNR1 (0.48) | CNR1CNR2RAB9AKDM4ENPC1 | |
| SCHEMBL24718226 | 0.78 | CNR1 (0.48) | CNR1CNR2RAB9AKDM4ENPC1 | |
| SCHEMBL2886082 | 0.78 | KMT2A (0.49) | CNR1CNR2RAB9AGAANPC1 | |
| SCHEMBL20257271 | 0.75 | ALDH1A1 (0.49) | RAB9AKDM4EGAAALDH1A1NPC1 | |
| SCHEMBL24353844 | 0.75 | POLB (0.44) | CNR1CNR2RAB9ANPC1ATM | |
| SCHEMBL422365 | 0.74 | CNR1 (0.44) | CNR1CNR2RAB9AGAANPC1 | |
| SCHEMBL12897088 | 0.73 | CA1 (0.59) | CNR1CNR2RAB9AGAAALDH1A1 | |
| SCHEMBL6301076 | 0.72 | NPC1 (0.57) | RAB9AKDM4EALDH1A1NPC1ATM | |
| SCHEMBL25903326 | 0.71 | TAAR1 (0.41) | KDM4EGAAALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CNR1 11/4885CNR2 16/4885RAB9A 2043/4885 |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | ADRA1A, ADRA1D, ADRB1 | CNR1 177/4885CNR2 387/4885RAB9A 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.